Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Attractin Mediates Invasiveness of Certain Brain Tumors

By Biotechdaily staff writers
Posted on 01 Dec 2006
Cancer researchers have found that the protein attractin, which is produced by cells present in certain types of brain tumors, is an important mediator of tumor invasiveness and a reliable biomarker for the detection of malignant astrocytoma.

Investigators at Emory University (Atlanta, GA, USA) used advanced proteomic techniques to analyze cerebrospinal fluid (CSF) or cyst fluid samples from 60 patients with various diseases of the central nervous system. More...
They found that attractin was consistently elevated in the samples from patients with malignant astrocytoma, a common and highly aggressive type of brain cancer.

To independently validate these results, they examined attractin expression in a new set of 108 normal and tumoral brain tissue specimens and found elevated expression in 97% of malignant astrocytomas, with the highest levels found in grade four tumors. Immunohistochemical data published in the November 2006 issue of Clinical Cancer Research showed that attractin was produced and secreted by the tumor cells. Furthermore, cerebrospinal fluid from brain tumor patients induced glioma cell migration, and attractin was largely responsible for this promigratory activity.

"Using proteomic analyses of the CSF of patients with brain tumors, we have identified for the first time that attractin levels are elevated in patients with high-grade astrocytoma,” said senior author Dr. Erwin Van Meir, professor of neurosurgery and hematology/oncology at Emory University. "Because few noninvasive methods are available for monitoring CNS malignancies, there is an urgent need to find reliable indicators. Our studies suggest that measuring attractin levels in patients with grades II-IV astrocytoma should be explored further as a potential biomarker for monitoring the growth of these tumors or as a potential new target for therapy.”



Related Links:
Emory University

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.